NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics ForumWALTHAM, Mass.--(BUSINESS WIRE)--Nov. 27, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, today announced that Shai N.
Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled
to speak at the
Canaccord Genuity Medical Technology & Diagnostics Forum
at the Le Parker Meridien,
New York, NY on
December 4, 2012. Dr. Gozani
intends to provide an update on the Company’s business activities and on
its diabetes products including NC-stat
® DPNCheck
™,
a diagnostic test for systemic neuropathies such as diabetic peripheral
neuropathy (DPN), and the SENSUS
™ pain management device for
relief of chronic intractable pain.
NeuroMetrix's presentation is scheduled for Tuesday, December 4, 2012 at
11:30 am (Eastern Daylight Time). A live audio webcast will be available
on the investor relations section of the corporate website - www.neurometrix.com.
This webcast will be archived after the live event.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians in retail
health settings such as pharmacies, and by managed care organizations to
optimize patient care and reduce healthcare costs. The company markets
the NC-stat® DPNCheck™ device, which is a rapid, accurate,
and quantitative point-of-care test for diabetic neuropathy. This
product is used to detect diabetic neuropathy at an early stage and to
guide treatment. The company is in late stage development of SENSUS™, a
pain management device which recently received Food and Drug
Administration clearance. The company has additional therapeutic
products in its pipeline. For more information, please visit http://www.neurometrix.com.
Source: NeuroMetrix
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
